Skip to main content
SpringerLink
Log in

Switch to another drug or try adjunctive therapy in patients with treatment-resistant obsessive-compulsive disorder

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011; 25(7): 585–96

    Article  PubMed  CAS  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association, 2000

  3. Goodman W, Price L, Rasmussen S, et al. The Yale Brown Obsessive Compulsive Scale: validity. Arch Gen Psychiatry 1989; 46: 1012–6

    Article  PubMed  CAS  Google Scholar 

  4. Koran LM, Hanna GL, Hollander E, et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Psychiatric Association. Am J Psychiatry 2007 Jul; 164(7 Suppl.): 5–53

    PubMed  Google Scholar 

  5. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57(5): 184–9

    PubMed  CAS  Google Scholar 

  6. Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992 Nov; 161: 665–70

    Article  PubMed  CAS  Google Scholar 

  7. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997 Sep; 154(9): 1261–4

    PubMed  CAS  Google Scholar 

  8. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996 Jul; 57(7): 303–6

    PubMed  CAS  Google Scholar 

  9. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000 Aug; 57(8): 794–801

    Article  PubMed  CAS  Google Scholar 

  10. Hollander E, Baldini Rossi N, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003 Dec; 6(4): 397–401

    Article  PubMed  CAS  Google Scholar 

  11. D’Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003 Jun; 27(4): 619–23

    Article  PubMed  Google Scholar 

  12. Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000 Oct 30; 96(2): 91–8

    Article  PubMed  CAS  Google Scholar 

  13. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004 Mar 1; 55(5): 553–5

    Article  PubMed  CAS  Google Scholar 

  14. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002 May; 17(3): 115–9

    Article  PubMed  CAS  Google Scholar 

  15. Denys D, deGeus F, van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004 Aug; 65(8): 1040–8

    Article  PubMed  CAS  Google Scholar 

  16. Fineberg NA, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005 Jul; 20(4): 223–6

    Article  PubMed  Google Scholar 

  17. Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009 Sep; 24(5): 265–9

    Article  PubMed  Google Scholar 

  18. Metin O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003 Aug; 18(6): 463–7

    Article  PubMed  CAS  Google Scholar 

  19. Marazziti D, Golia F, Consoli G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 2008 Nov; 13(11): 971–6

    PubMed  Google Scholar 

  20. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991 Jun; 11(3): 175–84

    Article  PubMed  CAS  Google Scholar 

  21. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006; 23(1): 1–5

    Article  Google Scholar 

  22. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003 May; 167(2): 219–20

    CAS  Google Scholar 

  23. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009 Nov; 70(11): 1530–5

    Article  PubMed  CAS  Google Scholar 

  24. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000 May; 10(3): 165–9

    Article  PubMed  CAS  Google Scholar 

  25. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998 Sep; 13(5): 219–24

    Article  PubMed  CAS  Google Scholar 

  26. Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 2004 Jul–Sep; 16(3): 127–32

    Article  PubMed  Google Scholar 

  27. Amiaz R, Fostick L, Gershon A, et al. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008 Jun; 18(6): 455–61

    Article  PubMed  CAS  Google Scholar 

  28. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 1999 Sep; 2(3): 193–5

    Article  PubMed  CAS  Google Scholar 

  29. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002 Sep; 63(9): 796–801

    Article  PubMed  CAS  Google Scholar 

  30. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998 Oct; 55(10): 918–24

    Article  PubMed  CAS  Google Scholar 

  31. Koran LM, Pallanti S, Paiva RS, et al. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol 1998 May; 8(2): 121–6

    Article  PubMed  CAS  Google Scholar 

  32. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997 Mar; 154(3): 396–401

    PubMed  CAS  Google Scholar 

  33. Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006 Feb; 26(1): 79–83

    Article  PubMed  CAS  Google Scholar 

  34. Vulink NC, Denys D, Fluitman SB, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry 2009 Jul; 70(7): 1001–8

    Article  PubMed  CAS  Google Scholar 

  35. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004 Oct; 65(10): 1394–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Switch to another drug or try adjunctive therapy in patients with treatment-resistant obsessive-compulsive disorder. Drugs Ther Perspect 28, 14–18 (2012). https://doi.org/10.2165/11606260-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606260-000000000-00000

Search

Navigation